NEW YORK, April 10 - Sequenom and Provid Pharmaceuticals today said they plan to co-develop small-molecule therapeutics based on cardiovascular targets discovered by Sequenom.
 
Terms of the deal call for privately held Provid to receive an equity investment and research funding, and to be eligible for milestones and royalties on any products that may arise.

Financial details of the collaboration were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.